Systems & synthetic biologist, proteomics, bioinformatics; Professor of Molecular Biosciences @ UT Austin; Cofounder, Erisyonhttps://bsky.app/profile/edwardmarcotte.bsky.socialhttps://bsky.app/profile/edwardmarcotte.bsky.social/post/3mtuhgudp6k2gThe window for public comments is still open but closes soon (tonight!) for NSF's proposed changes to require approval by political appointees, add restrictions to publishing & communication of research, and ban international collaborations. [contains quote post or other embedded content]24 Aug 2026 23:28 +0000at://did:plc:ayubcq3bb5r2bphswdcyuzmp/app.bsky.feed.post/3mtuhgudp6k2ghttps://bsky.app/profile/edwardmarcotte.bsky.social/post/3mthrnvotl22cExciting news for personalized mRNA cancer vaccines, especially if the phase 3 effect size matches the phase 2 trial (49% reduced death or recurrence), although we have to wait for the official numbers https://arstechnica.com/health/2026/08/mrna-cancer-vaccine-succeeded-in-phase-3-melanoma-trial-moderna-and-merck-say/19 Aug 2026 22:27 +0000at://did:plc:ayubcq3bb5r2bphswdcyuzmp/app.bsky.feed.post/3mthrnvotl22c